Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19908750 | 0.86 | HSD17B10 (0.41) | NOTUMALDH1A1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL30463983 | 0.86 | HSD17B10 (0.41) | NOTUMALDH1A1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL21008360 | 0.82 | ALDH1A1 (0.37) | NOTUMALDH1A1HSD17B10SRD5A1KDM4E | |
| SCHEMBL24383360 | 0.82 | NOTUM (0.39) | NOTUMALDH1A1HSD17B10SRD5A1KDM4E | |
| SCHEMBL17833067 | 0.82 | ALDH1A1 (0.38) | NOTUMALDH1A1HSD17B10SRD5A1KDM4E | |
| SCHEMBL2616784 | 0.77 | NOTUM (0.58) | NOTUMALDH1A1SRD5A1KDM4ESMN1; SMN2 | |
| SCHEMBL2625792 | 0.76 | ALDH1A1 (0.50) | NOTUMALDH1A1HSD17B10SRD5A1KDM4E | |
| SCHEMBL18363028 | 0.74 | ALDH1A1 (0.44) | NOTUMALDH1A1HSD17B10SRD5A1KDM4E | |
| SCHEMBL21760551 | 0.74 | CASP3 (0.41) | NOTUMALDH1A1KDM4EGAAMAPT | |
| SCHEMBL23761222 | 0.74 | ALDH1A1 (0.47) | NOTUMALDH1A1KDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012064744-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORϒ ACTIVITY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | NOTUM 3565/4885ALDH1A1 988/4885HSD17B10 2526/4885 |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | NOTUM 3840/4885ALDH1A1 2852/4885HSD17B10 3972/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | NOTUM 4606/4885ALDH1A1 2826/4885HSD17B10 2257/4885 |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | NOTUM 2185/4885ALDH1A1 1659/4885HSD17B10 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.